PFM Health Sciences LP has recently announced that it has increased stake in Caribou Biosciences Inc (NASDAQ:CRBU) by 20.71%. After grabbing 6.72 million shares, the institutional investor is now in possession of 1.15 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 7.60% having worth around $39.47 million. Moreover, Avidity Partners Management LP increased its share by 3.29 million to have a control over 6.05 million shares. And BlackRock Fund Advisors raised its holdings to 1.3 million shares by acquiring 5.43 million shares or 6.15% of the stake.
Caribou Biosciences Inc (CRBU) concluded trading on 01/10/24 at a closing price of $5.96, with 3.43 million shares of worth about $20.46 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -23.20% during that period and on Wednesday the price saw a gain of about 3.83%. Currently the company’s common shares owned by public are about 88.43M shares, out of which, 74.54M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 3 times over the past 12 months. They bought 20,000 shares in 2 of the transactions. In 1 selling transactions, insiders dumped 5,627 shares.
SPDR S&P Biotech ETF, Vanguard Total Stock Market ETF, and Pictet – Biotech are the top 3 mutual funds which are holding stakes in Caribou Biosciences Inc SPDR S&P Biotech ETF is currently holding 4.46 million shares of worth totaling $26.18 million. The company recently came buying 20790.0 shares which brought its stake up to 5.04% of the company’s outstanding shares. Pictet – Biotech, after buying 1.8 million shares, have now control over 2.04% of the stake in the company. It holds 0.35 million shares of worth $10.59 million.
Caribou Biosciences Inc (NASDAQ: CRBU) started trading at $5.71, below -$0.03 from concluding price of the previous day. However, the stock later moved at a day high price of 6.03, or with a gain of 3.83%. Stock saw a price change of 14.62% in past 5 days and over the past one month there was a price change of 2.58%. Year-to-date (YTD), CRBU shares are showing a performance of 4.01% which decreased to -13.62% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.44 but also hit the highest price of $8.59 during that period. The average intraday trading volume for Caribou Biosciences Inc shares is 1.67 million. The stock is currently trading 2.94% above its 20-day simple moving average (SMA20), while that difference is up 13.23% for SMA50 and it goes to 14.32% higher than SMA200.
PFM Health Sciences LP acquired 6.72 million shares of Caribou Biosciences Inc having value of about $39.47 million. Data submitted at the U.S SEC by PFM Health Sciences LP revealed that the firm now holds 1.15 million shares in the company valued at close to $6876922.16, or have control over 20.71% stake in the company. Caribou Biosciences Inc (NASDAQ: CRBU) currently have 88.43M outstanding shares and institutions hold larger chunk of about 76.89% of that. Holding of mutual funds in the company is about 4.88% while other institutional holders and individual stake holders have control over 50.00% and 26.56% of the stake respectively.
The stock has a current market capitalization of $527.04M and its 3Y-monthly beta is at 2.49. It has posted earnings per share of -$1.50 in the same period. It has Quick Ratio of 14.27 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRBU, volatility over the week remained 10.77% while standing at 8.15% over the month.
Analysts are in expectations that Caribou Biosciences Inc (CRBU) stock would likely to be making an EPS of -$0.4 in the current quarter, while forecast for next quarter EPS is -$0.41 and it is -$1.74 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.48 which is -$0.21 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.44 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 14.42% while it is estimated to decrease by -24.01% in next year.
Analysts at 9 brokerage firms have issued recommendations for the Caribou Biosciences Inc (CRBU)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.22. Out of those 9 Wall Street analysts, 8 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
